NV-103

N/A

Report date: 2025/07/03 11:47:54

Base Information

Drug NameNV-103

Drug Alias Nameanti-CD99 TNS (CD99-TNS/Ir)Antibody-conjugated irinotecan liposomal nanoparticleNV-103

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Irinotecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionDNA topoisomerase inhibitorsAnti-CD99 antigen

TargetsDNA topoisomeraseCD99 antigen

Therapy Area/IndicationsGlioblastomaSarcoma, Ewing

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNanovalent Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesNanovalent Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsGlioblastomaSarcoma, Ewing

Inactive IndicationsN/A

Other Information

ATC CodeN/A